Development of PET and SPECT Probes for Glutamate Receptors

l-Glutamate and its receptors (GluRs) play a key role in excitatory neurotransmission within the mammalian central nervous system (CNS). Impaired regulation of GluRs has also been implicated in various neurological disorders. GluRs are classified into two major groups: ionotropic GluRs (iGluRs), which are ligand-gated ion channels, and metabotropic GluRs (mGluRs), which are coupled to heterotrimeric guanosine nucleotide binding proteins (G-proteins). Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of GluRs could provide a novel view of CNS function and of a range of brain disorders, potentially leading to the development of new drug therapies. Although no satisfactory imaging agents have yet been developed for iGluRs, several PET ligands for mGluRs have been successfully employed in clinical studies. This paper reviews current progress towards the development of PET and SPECT probes for GluRs.

[1]  Richard J. Edwards,et al.  Metabotropic Glutamate Receptors , 2015, The Journal of Biological Chemistry.

[2]  Pedro Rosa-Neto,et al.  Limbic system mGluR5 availability in cocaine dependent subjects: A high-resolution PET [11C]ABP688 study , 2014, NeuroImage.

[3]  P. Zanotti-Fregonara,et al.  [18F]FIMX is a promising tracer to quantify metabotropic glutamate receptor 1 (mGluR1) in human brain , 2014 .

[4]  Lin Xie,et al.  PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate. , 2014, American journal of nuclear medicine and molecular imaging.

[5]  Lin Xie,et al.  Noninvasive Quantification of Metabotropic Glutamate Receptor Type 1 with [11C]ITDM: a Small-Animal PET Study , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  Hyejin Kang,et al.  In Vivo Imaging of mGluR5 Changes during Epileptogenesis Using [11C]ABP688 PET in Pilocarpine-Induced Epilepsy Rat Model , 2014, PloS one.

[7]  Alexander Hammers,et al.  Initial Evaluation of 18F-GE-179, a Putative PET Tracer for Activated N-Methyl d-Aspartate Receptors , 2014, The Journal of Nuclear Medicine.

[8]  N. Pitsikas.  The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders? , 2014, European journal of pharmacology.

[9]  Richard E. Carson,et al.  Imaging Glutamate Homeostasis in Cocaine Addiction with the Metabotropic Glutamate Receptor 5 Positron Emission Tomography Radiotracer [11C]ABP688 and Magnetic Resonance Spectroscopy , 2014, Biological Psychiatry.

[10]  Ming-Rong Zhang,et al.  Binding potential of (E)-[¹¹C]ABP688 to metabotropic glutamate receptor subtype 5 is decreased by the inclusion of its ¹¹C-labelled Z-isomer. , 2014, Nuclear medicine and biology.

[11]  Alexander Hammers,et al.  Initial Evaluation of 18 F-GE-179 , A Putative PET Tracer for Activated N-Methyl D-Aspartate Receptors , 2014 .

[12]  Andrew C. Hooker,et al.  A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 — Estimating occupancy in the absence of a reference region , 2013, NeuroImage.

[13]  Paolo Zanotti-Fregonara,et al.  Synthesis and evaluation in monkey of [(18)F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([(18)F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1). , 2013, Journal of medicinal chemistry.

[14]  K. Jokivarsi,et al.  Radiosynthesis of N-(4-chloro-3-[(11)C]methoxyphenyl)-2-picolinamide ([(11)C]ML128) as a PET radiotracer for metabotropic glutamate receptor subtype 4 (mGlu4). , 2013, Bioorganic & medicinal chemistry.

[15]  Ming-Rong Zhang,et al.  Monitoring Neuroprotective Effects Using Positron Emission Tomography With [11C]ITMM, a Radiotracer for Metabotropic Glutamate 1 Receptor , 2013, Stroke.

[16]  Keiichi Oda,et al.  Initial Human PET Studies of Metabotropic Glutamate Receptor Type 1 Ligand 11C-ITMM , 2013, The Journal of Nuclear Medicine.

[17]  F. Gasparini,et al.  Metabotropic Glutamate Receptors for Parkinson's Disease Therapy , 2013, Parkinson's disease.

[18]  S. Chaki,et al.  mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants , 2013, Neuropharmacology.

[19]  James Robert Brašić,et al.  18F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry , 2013, The Journal of Nuclear Medicine.

[20]  G. Fisone,et al.  Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease , 2013, Neuropharmacology.

[21]  V. Treyer,et al.  Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography , 2012, Proceedings of the National Academy of Sciences.

[22]  J. Maeda,et al.  Development of N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methyl-4-[11C]methylbenzamide for positron emission tomography imaging of metabotropic glutamate 1 receptor in monkey brain. , 2012, Journal of medicinal chemistry.

[23]  G. Bormans,et al.  Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. , 2012, Journal of medicinal chemistry.

[24]  Ming-Rong Zhang,et al.  In Vivo Measurement of the Affinity and Density of Metabotropic Glutamate Receptor Subtype 1 in Rat Brain Using 18F-FITM in Small-Animal PET , 2012, The Journal of Nuclear Medicine.

[25]  Yiyun Huang,et al.  Synthesis and characterization of two pet radioligands for the metabotropic glutamate 1 (mGlu1) receptor , 2012, Synapse.

[26]  L. Barré,et al.  Synthesis and in vitro characterization of trans- and cis-[(18)F]-4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]-3-fluoropiperidine-1-carboxylates as new potential PET radiotracer candidates for the NR2B subtype N-methyl-D-aspartate receptor. , 2012, European journal of medicinal chemistry.

[27]  Mark E. Schmidt,et al.  Biodistribution, dosimetry and kinetic modeling of [11C]JNJ-42491293, a PET tracer for the mGluR2 receptor in the human brain , 2012 .

[28]  T. Suhara,et al.  Characterization of 1‐(2‐[18F]fluoro‐3‐pyridyl)‐4‐(2‐isopropyl‐1‐oxo‐ isoindoline‐5‐yl)‐5‐methyl‐1H‐1,2,3‐triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains , 2012, Journal of neurochemistry.

[29]  P. Conn,et al.  Metabotropic glutamate receptors as therapeutic targets for schizophrenia , 2012, Neuropharmacology.

[30]  D. McKinzie,et al.  Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia , 2012, Neuropharmacology.

[31]  Lin Xie,et al.  Synthesis and evaluation of novel radioligands for positron emission tomography imaging of metabotropic glutamate receptor subtype 1 (mGluR1) in rodent brain. , 2012, Journal of medicinal chemistry.

[32]  H. Lane,et al.  Glutamate signaling in the pathophysiology and therapy of schizophrenia , 2012, Pharmacology Biochemistry and Behavior.

[33]  W. Marsden.  I and J , 2012 .

[34]  T. Suhara,et al.  Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [18F]FITM , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  T. Salt,et al.  Metabotropic glutamate receptors in the thalamocortical network: Strategic targets for the treatment of absence epilepsy , 2011, Epilepsia.

[36]  Gregor Hasler,et al.  Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. , 2011, The American journal of psychiatry.

[37]  Hiro Furukawa,et al.  Subunit Arrangement and Phenylethanolamine Binding in GluN1/GluN2B NMDA Receptors , 2011, Nature.

[38]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[39]  Ming-Rong Zhang,et al.  Radiosynthesis and preliminary evaluation of 4-[18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. , 2011, Bioorganic & medicinal chemistry letters.

[40]  Sandra M. Sanabria-Bohórquez,et al.  Synthesis, characterization, and monkey PET studies of [18F]MK‐1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK‐5435 , 2011, Synapse.

[41]  Y. Magata,et al.  Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor. , 2010, Bioorganic & medicinal chemistry.

[42]  D. Javitt,et al.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia? , 2010, Brain Research Bulletin.

[43]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[44]  J. Kemp,et al.  3′‐(Arylmethyl)‐ and 3′‐(Aryloxy)‐3‐phenyl‐4‐hydroxyquinolin‐2(1H)‐ ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor. , 2010 .

[45]  F. Weiss,et al.  Behavioral and Functional Evidence of Metabotropic Glutamate Receptor 2/3 and Metabotropic Glutamate Receptor 5 Dysregulation in Cocaine-Escalated Rats: Factor in the Transition to Dependence , 2010, Biological Psychiatry.

[46]  Ming-Rong Zhang,et al.  Radiosynthesis and evaluation of [11C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1. , 2010, Nuclear medicine and biology.

[47]  C. Low,et al.  New Insights into the Not-So-New NR3 Subunits of N-Methyl-d-aspartate Receptor: Localization, Structure, and Function , 2010, Molecular Pharmacology.

[48]  A. Lau,et al.  Glutamate receptors, neurotoxicity and neurodegeneration , 2010, Pflügers Archiv - European Journal of Physiology.

[49]  S. Luthra,et al.  Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET. , 2010, Bioorganic & medicinal chemistry letters.

[50]  G. Suzuki,et al.  Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[51]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[52]  C. Low,et al.  New Insights into the Not-So-New NR 3 Subunits of N-Methyl-D-aspartate Receptor : Localization , Structure , and Function , 2010 .

[53]  R. Huganir,et al.  Dual Palmitoylation of NR2 Subunits Regulates NMDA Receptor Trafficking , 2009, Neuron.

[54]  M. Hata,et al.  Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. , 2009, Bioorganic & medicinal chemistry letters.

[55]  Y. Magata,et al.  Development of N-[11C]methylamino 4-hydroxy-2(1H)-quinolone derivatives as PET radioligands for the glycine-binding site of NMDA receptors. , 2009, Bioorganic & medicinal chemistry.

[56]  J. Kew,et al.  Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential , 2009, British journal of pharmacology.

[57]  P Jeffrey Conn,et al.  Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). , 2009, Journal of medicinal chemistry.

[58]  R. M. Stewart,et al.  Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease , 2009, Journal of clinical pharmacology.

[59]  Craig W Lindsley,et al.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. , 2009, Trends in pharmacological sciences.

[60]  S. Zoghbi,et al.  Radiodefluorination of 3-Fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203), a Radioligand for Imaging Brain Metabotropic Glutamate Subtype-5 Receptors with Positron Emission Tomography, Occurs by Glutathionylation in Rat Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[61]  Jeih-San Liow,et al.  Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET , 2008, Journal of Nuclear Medicine.

[62]  Ehud Y Isacoff,et al.  Rules of engagement for NMDA receptor subunits , 2008, Proceedings of the National Academy of Sciences.

[63]  Peter L. Freddolino,et al.  Molecular mechanism of ligand recognition by NR3 subtype glutamate receptors , 2008, The EMBO journal.

[64]  Suneil K. Kalia,et al.  NMDA receptors in clinical neurology: excitatory times ahead , 2008, The Lancet Neurology.

[65]  E. Donny,et al.  Metabotropic Glutamate 5 Receptor (mGluR5) Antagonists Decrease Nicotine Seeking, But Do Not Affect the Reinforcement Enhancing Effects of Nicotine , 2008, Neuropsychopharmacology.

[66]  D. Bowie.  Ionotropic glutamate receptors & CNS disorders. , 2008, CNS & neurological disorders drug targets.

[67]  John Q. Wang,et al.  Upregulation of metabotropic glutamate receptor 8 mRNA expression in the rat forebrain after repeated amphetamine administration , 2008, Neuroscience Letters.

[68]  Y. Magata,et al.  Difference in brain distributions of carbon 11-labeled 4-hydroxy-2(1H)-quinolones as PET radioligands for the glycine-binding site of the NMDA ion channel. , 2008, Nuclear medicine and biology.

[69]  Robert W. Gereau,et al.  The Glutamate Receptors , 2008 .

[70]  A. Brownell,et al.  Synthesis and preliminary biological evaluation of 3‐[18F]fluoro‐5‐(2‐pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5 , 2007, Synapse.

[71]  Hidehiko Takahashi,et al.  Measurement of glycine binding site of N‐methyl‐d‐asparate receptors in living human brain using 4‐acetoxy derivative of L‐703,717, 4‐acetoxy‐7‐chloro‐3‐[3‐(4‐[11c] methoxybenzyl) phenyl]‐2(1H)‐quinolone (AcL703) with positron emission tomography , 2007, Synapse.

[72]  A. Biegon,et al.  In vitro and in vivo characterization of [3H]CNS‐5161—A use‐dependent ligand for the N‐methyl‐d‐aspartate receptor in rat brain , 2007, Synapse.

[73]  H. Beck,et al.  Loss of Metabotropic Glutamate Receptor-Dependent Long-Term Depression via Downregulation of mGluR5 after Status Epilepticus , 2007, The Journal of Neuroscience.

[74]  Sami S Zoghbi,et al.  Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. , 2007, Journal of medicinal chemistry.

[75]  D. Purpura,et al.  NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders , 2007, Nature Reviews Neuroscience.

[76]  Mark E. Schmidt,et al.  Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  P. Paoletti,et al.  NMDA receptor subunits: function and pharmacology. , 2007, Current opinion in pharmacology.

[78]  S. Luthra,et al.  Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine. , 2006, Bioorganic & medicinal chemistry.

[79]  Francesco Ferraguti,et al.  Metabotropic glutamate receptors , 2006, Cell and Tissue Research.

[80]  Yves P Auberson,et al.  Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[81]  K. Gogas.  Glutamate-based therapeutic approaches: NR2B receptor antagonists. , 2006, Current opinion in pharmacology.

[82]  J. Krystal,et al.  First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients , 2006, Molecular Psychiatry.

[83]  E. Gouaux,et al.  Subunit arrangement and function in NMDA receptors , 2005, Nature.

[84]  Karolina Nilsson,et al.  Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. , 2005, Current topics in medicinal chemistry.

[85]  Yiyun Huang,et al.  A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-ethyl-2-[11C]methyl-6-quinolinyl)(cis- 4-methoxycyclohexyl)methanone. , 2005, Journal of medicinal chemistry.

[86]  J. Krystal,et al.  Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo , 2005, Biological Psychiatry.

[87]  Christine Ryan,et al.  Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers , 2005, Synapse.

[88]  J. Kemp,et al.  Ionotropic and metabotropic glutamate receptor structure and pharmacology , 2005, Psychopharmacology.

[89]  A. Markou,et al.  The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats , 2005, Psychopharmacology.

[90]  M. Kassiou,et al.  Radiosynthesis and in vivo evaluation of [11C]Ro-647312: a novel NR1/2B subtype selective NMDA receptor radioligand , 2004 .

[91]  M. Laruelle,et al.  In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxy-phenyl)-N'-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor. , 2004, Nuclear medicine and biology.

[92]  M. Kassiou,et al.  Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors. , 2004, Bioorganic & medicinal chemistry.

[93]  Roger N Gunn,et al.  A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. , 2004, Nuclear medicine and biology.

[94]  D. Brooks,et al.  Initial kinetic analyses of the in vivo binding of the putative NMDA receptor ligand [C-11]CNS 5161 in humans , 2004 .

[95]  Hyoung-Gon Lee,et al.  The role of metabotropic glutamate receptors in Alzheimer's disease. , 2004, Acta neurobiologiae experimentalis.

[96]  J. Kemp,et al.  Identification of Critical Residues in the Amino Terminal Domain of the Human NR2B Subunit Involved in the RO 25-6981 Binding Pocket , 2003, Journal of Pharmacology and Experimental Therapeutics.

[97]  M. Kassiou,et al.  Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[(11)C]one, as a potent NR(1A)/2B subtype selective NMDA PET radiotracer. , 2003, Bioorganic & medicinal chemistry.

[98]  Ming-Rong Zhang,et al.  Effects of endogenous agonists, glycine and D‐serine, on in vivo specific binding of [11C]L‐703,717, a PET radioligand for the glycine‐binding site of NMDA receptors , 2003, Synapse.

[99]  Eric Gouaux,et al.  Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand‐binding core , 2003, The EMBO journal.

[100]  M. Piel,et al.  Synthesis and evaluation of 5,7‐dichloro‐4‐(3‐{4‐[4‐(2‐[18F]fluoroethyl)‐piperazin‐1‐yl]‐phenyl}‐ureido)‐1,2,3,4‐tetrahydroquinoline‐2‐carboxylic acid as a potential NMDA ligand to study glutamatergic neurotransmission in vivo , 2003 .

[101]  R. Gunn,et al.  Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor. , 2003, Nuclear medicine and biology.

[102]  B. Platt,et al.  Glutamate receptor function in learning and memory , 2003, Behavioural Brain Research.

[103]  M. Laruelle,et al.  In vivo evaluation of [11C]-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6-dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel. , 2002, Nuclear medicine and biology.

[104]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[105]  T. Suhara,et al.  Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (+/-)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors. , 2002, Nuclear medicine and biology.

[106]  L. R. Merlin.  Differential roles for mGluR1 and mGluR5 in the persistent prolongation of epileptiform bursts. , 2002, Journal of neurophysiology.

[107]  K. Roche,et al.  Molecular determinants of NMDA receptor internalization , 2001, Nature Neuroscience.

[108]  T. Suhara,et al.  A prodrug of NMDA/glycine site antagonist, L-703,717, with improved BBB permeability: 4-acetoxy derivative and its positron-emitter labeled analog. , 2001, Chemical & pharmaceutical bulletin.

[109]  J. Mcculloch,et al.  Synthesis and binding characteristics of N-(1-naphthyl)-N'-(3-[(125)I]-iodophenyl)-N'-methylguanidine ([(125)I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation. , 2000, Nuclear medicine and biology.

[110]  T. Okauchi,et al.  A strategy for increasing the brain uptake of a radioligand in animals: use of a drug that inhibits plasma protein binding. , 2000, Nuclear medicine and biology.

[111]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[112]  P. van Bladeren,et al.  Conjugation of isoprene monoepoxides with glutathione, catalyzed by alpha, mu, pi and theta-class glutathione S-transferases of rat and man. , 1999, Chemico-biological interactions.

[113]  P. J. Bladeren,et al.  Conjugation of isoprene monoepoxides with glutathione, catalyzed by α, μ, π and θ-class glutathione S-transferases of rat and man , 1999 .

[114]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[115]  H. Betz,et al.  Evidence for a Tetrameric Structure of Recombinant NMDA Receptors , 1998, The Journal of Neuroscience.

[116]  H. Onoe,et al.  In vitro and in vivo characterization of (+)-3-[11C]cyano-dizocilpine , 1998, Journal of Neural Transmission.

[117]  P D Leeson,et al.  Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. , 1997, Journal of medicinal chemistry.

[118]  F. Menniti,et al.  CP-101,606, a potent neuroprotectant selective for forebrain neurons. , 1997, European journal of pharmacology.

[119]  S. Snyder,et al.  d-Serine as a Neuromodulator: Regional and Developmental Localizations in Rat Brain Glia Resemble NMDA Receptors , 1997, The Journal of Neuroscience.

[120]  J. Rossier,et al.  Neuronal activity differentially regulates NMDA receptor subunit expression in cerebellar granule cells , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[121]  M. Mishina,et al.  Structure and function of the NMDA receptor channel , 1995, Neuropharmacology.

[122]  S. Snyder,et al.  D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[123]  P. Leeson,et al.  3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. , 1994, Journal of medicinal chemistry.

[124]  T. Nishikawa,et al.  Synthesis and evaluation of 1-(1-[5-(2'-[18F]fluoroethyl)-2-thienyl]-cyclohexyl)piperidine as a potential in vivo radioligand for the NMDA receptor-channel complex. , 1993, Nuclear medicine and biology.

[125]  T. Nishikawa,et al.  Endogenous d‐Serine in Rat Brain: N‐Methyl‐d‐Aspartate Receptor‐Related Distribution and Aging , 1993, Journal of neurochemistry.

[126]  E. Kandel,et al.  Proceedings of the National Academy of Sciences of the United States of America. Annual subject and author indexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[127]  P. Franzone,et al.  An in vivo evaluation , 1989 .

[128]  E. Wong,et al.  [3H]MK‐801 Labels a Site on the N‐Methyl‐D‐Aspartate Receptor Channel Complex in Rat Brain Membranes , 1988, Journal of neurochemistry.

[129]  E. Wong,et al.  The novel anticonvulsant MK‐801 binds to the activated state of the N‐methyl‐d‐aspartate receptor in rat brain , 1987, British journal of pharmacology.

[130]  M. Williams,et al.  Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists. , 1986, European journal of pharmacology.

[131]  D. Lodge,et al.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.

[132]  John O’M. Bockris,et al.  Mechanisms of Activation , 1979 .

[133]  R. Stephenson.  A and V , 1962, The British journal of ophthalmology.